Pemigatinib (Standard)

CAT: 0804-HY-109099R-01Size: 5 mgDry Ice: NoHazardous: No

1 / 1

CAT#:0804-HY-109099R-01Size:5 mg

Selected

24/48H Stock Items & 2 to 6 Weeks non Stock Items.

Quick Request Actions

Description

Pemigatinib (Standard) is the analytical standard of Pemigatinib. This product is intended for research and analytical applications. Pemigatinib (INCB054828) is an orally active, selective FGFR inhibitor with IC50s of 0.4 nM, 0.5 nM, 1.2 nM, 30 nM for FGFR1, FGFR2, FGFR3, FGFR4, respectively. Pemigatinib has the potential for cholangiocarcinoma[1][2].

CAS Number

1513857-77-6

Product Name Alternative

INCB054828 (Standard)

UNSPSC

12352005

Target

FGFR; Reference Standards

Type

Reference Standards

Related Pathways

Others; Protein Tyrosine Kinase/RTK

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/pemigatinib-standard.html

Smiles

CCN(C(N(C(C(F)=C(OC)C=C1OC)=C1F)C2)=O)C(C2=CN3)=C4C3=NC(CN5CCOCC5)=C4

Molecular Formula

C24H27F2N5O4

Molecular Weight

487.50

References & Citations

[1]Arudra K, et al. Calcinosis cutis dermatologic toxicity associated with fibroblast growth factor receptor inhibitor for the treatment of Wilms tumor. J Cutan Pathol. 2018 Oct;45 (10) :786-790.|[2]Roskoski R Jr, et al. The role of fibroblast growth factor receptor (FGFR) protein-tyrosine kinase inhibitors in the treatment of cancers including those of the urinary bladder. Pharmacol Res. 2020 Jan;151:104567.|[3]Krook MA, et al. Tumor heterogeneity and acquired drug resistance in FGFR2-fusion-positive cholangiocarcinoma through rapid research autopsy. Cold Spring Harb Mol Case Stud. 2019 Aug 1;5 (4) .

Shipping Conditions

Room temperature

Scientific Category

Reference Standards

Chemical Information

Pemigatinib

Pemigatinib is a small molecule kinase inhibitor with antitumour activity. It works by inhibiting fibroblast growth factor receptors (FGFRs), which are receptor tyrosine kinases that activate signalling pathways in tumour cells. FGFRs gained attention as potential therapeutic targets in selected cancers, as FGFR gene alterations were observed in a wide variety of cancers including those of the urinary bladder, breast, ovary, prostate, endometrium, lung, and stomach. Deregulated FGFR signalling pathway can lead the development of oncogenes and tumour-promoting physiological processes, such as cancer cell proliferation, enhanced angiogenesis, and evasion of cell death. In April 2020, pemigatinib was approved by the FDA for the treatment of unresectable locally advanced or metastatic cholangiocarcinoma in previously treated adult patients with a fibroblast growth factor receptor 2 (FGFR2) gene fusion or other rearrangements as detected by an FDA-approved test. Cholangiocarcinoma is the most common primary malignancy affecting the biliary tract and the second most common primary hepatic malignancy. This malignancy accounts for 15% to 20% of primary hepatobiliary malignancies, which account for 13% of overall cancer-related global mortality. With increasing research on the pathogenesis of cholangiocarcinoma and potential therapeutic targets for anticancer drug treatment, recent studies show that up to 45% of patients with intrahepatic cholangiocarcinoma exhibited gene rearrangements resulting in oncogenic fibroblast growth factor 2 (FGFR2) fusion proteins. The FDA-approved indication for pemigatinib was granted under accelerated approval based on the overall response rate and duration of response in pre-marketing clinical trials. Pemigatinib is marketed under the brand name Pemazyre, and it is available as oral tablets.

CAS Number	1513857-77-6
PubChem CID	86705695
IUPAC Name	11-(2,6-difluoro-3,5-dimethoxyphenyl)-13-ethyl-4-(morpholin-4-ylmethyl)-5,7,11,13-tetrazatricyclo[7.4.0.02,6]trideca-1,3,6,8-tetraen-12-one
Molecular Formula	C24H27F2N5O4
Molecular Weight	487.5
XLogP	1.8
Topological Polar Surface Area	83.2
Hydrogen Bond Donor Count	1
Hydrogen Bond Acceptor Count	8
Rotatable Bond Count	6
Heavy Atom Count	35
Formal Charge	0
Complexity	731

SMILES

CCN1C2=C3C=C(NC3=NC=C2CN(C1=O)C4=C(C(=CC(=C4F)OC)OC)F)CN5CCOCC5

InChI

InChI=1S/C24H27F2N5O4/c1-4-30-21-14(11-27-23-16(21)9-15(28-23)13-29-5-7-35-8-6-29)12-31(24(30)32)22-19(25)17(33-2)10-18(34-3)20(22)26/h9-11H,4-8,12-13H2,1-3H3,(H,27,28)

InChIKey

HCDMJFOHIXMBOV-UHFFFAOYSA-N

Chemical Structure

2D Structure

CAS: 1513857-77-6

CID: 86705695

Formula: C24H27F2N5O4

MW: 487.5

Interactive 3D Structure

Loading 3D structure...

View on PubChem Raw 3D data

Computed Properties

Property	Value
Molecular Weight	487.5
XLogP3	1.8
Hydrogen Bond Donor Count	1
Hydrogen Bond Acceptor Count	8
Rotatable Bond Count	6
Exact Mass	487.20311068
Monoisotopic Mass	487.20311068
Topological Polar Surface Area	83.2 Å²
Heavy Atom Count	35
Formal Charge	0
Complexity	731
Isotope Atom Count	0
Defined Atom Stereocenter Count	0
Undefined Atom Stereocenter Count	0
Defined Bond Stereocenter Count	0
Undefined Bond Stereocenter Count	0
Covalently-Bonded Unit Count	1
Compound Is Canonicalized	Yes

Related Products

Catalog	Name
HY-109099-01	Pemigatinib
HY-W754878	Pemigatinib-d6
HY-P2274R	Argifin (Standard)
HY-N9362R	Emodinanthrone (Standard)
HY-N7948R	Isomaltotetraose (Standard)
HY-N7640R	Deoxylimonin (Standard)
HY-N7617R	Toralactone (Standard)
HY-N7541R	Antrodin A (Standard)
HY-N6739R	Beauvericin (Standard)
HY-N6687R	Calcimycin (Standard)

Alternative Products

Catalog	Name
B3204-5	Pemigatinib
MBS3611727-01	Pemigatinib(INCB054828)

Pemigatinib (Standard)

Chemical Information

Related Products

Alternative Products

Popular Products